RayzeBio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.rayzebio.com
Clinical Trials
7
Active:1
Completed:0
Trial Phases
3 Phases
Phase 1:4
Phase 3:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (57.1%)Phase 3
2 (28.6%)Not Applicable
1 (14.3%)Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Not Applicable
Not yet recruiting
- Conditions
- Carcinoid TumorPancreatic NETSolid TumorSomatostatin ReceptorGEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor DiseaseNeuroendocrine TumorsCarcinoid
- Interventions
- Drug: RYZ401
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT07165132
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06726161
- Locations
- 🇺🇸
Research Facility, Grand Rapids, Michigan, United States
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1
Recruiting
- Conditions
- Metastatic Breast CancerAdvanced Breast CancerHER2-negative Breast CancerER+ Breast Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06590857
- Locations
- 🇺🇸
Research Facility, Seattle, Washington, United States
🇺🇸Research Facilty, Salt Lake City, Utah, United States
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Phase 1
Recruiting
- Conditions
- SCLC,Extensive Stage
- Interventions
- Drug: RYZ101 Dose Level 1Drug: RYZ101 Dose Level 2Drug: RYZ101 Dose Level 3Drug: RYZ101 Dose Level -1
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT05595460
- Locations
- 🇵🇷
Research Facility, San Juan, Puerto Rico
🇺🇸Reserach Facility, Lexington, Kentucky, United States
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Phase 3
Recruiting
- Conditions
- GEP-NETPancreatic NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor DiseaseNeuroendocrine TumorsCarcinoid TumorCarcinoid
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT05477576
- Locations
- 🇪🇸
Research Facility, Zaragoza, Spain
News
No news found